Rosenson, Robert S.
Chen, Qinzhong
Najera, Sherwin D.
Lee, Martin L.
Cho, Daniel J.
Funding for this research was provided by:
Astra Zeneca
Article History
First Online: 3 August 2018
Compliance with Ethical Standards
:
: Dr. Rosenson reports having received research support from Akcea, Amgen, Medicines Company, and Regeneron. He has participated in Advisory Boards for Akcea, CVS Caremark, Regeneron, and received honoraria from Akcea, Amgen, Kowa, Pfizer, and Sanofi. In 2014, he attended an Advisory Board meeting for Astra Zeneca. Dr. Chen has no conflict of interest. Mr. Najera has no conflict of interest. Dr. Lee reports consulting fees from Rheovector, and Mr. Cho reports consulting fees from Rheovector.
: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. This trial was approved by the Institutional Review Board at the Icahn School of Medicine at Mount Sinai, New York, NY. Informed consent was obtained from all individual participants included in the study.
: Hema-kinesis is an investigator-initiated trial that was initiated and designed by investigators at the Cardiometabolics Unit at the Icahn School of Medicine. This trial was funded by an unrestricted grant from Astra Zeneca. The sponsor had no involvement in the study design, conduct, interpretation of results, or preparation of this manuscript. Dr. Rosenson has received research funding from Astra Zeneca and participated in an advisory board sponsored by Astra Zeneca in 2014. Dr. Chen and Mr. Najera have no disclosures. Dr. Lee has received consulting fees from Rheovector. Mr. Cho has received consulting fees from Rheovector.